Evidence map›Paper›PMID 21367761›Full record

Trial reportAnnals of the rheumatic diseases2011

Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI.

Lukas Martin Wildi, Jean-Pierre Raynauld, Johanne Martel-Pelletier, André Beaulieu, Louis Bessette, Frédéric Morin, François Abram, Marc Dorais, Jean-Pierre Pelletier

Registry-linked trialOpen access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Annals of the rheumatic diseases, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00604539 (Study of the Effect of Chondroitin Sulphate on Synovial Inflammation in Patients With Osteoarthritis of the Knee), which is not on this map. Cited by 72 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed, 9 pooled it
15.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00604539 phase3completednot on this map

Study of the Effect of Chondroitin Sulphate on Synovial Inflammation in Patients With Osteoarthritis of the Knee

TypeinterventionalSponsorBioibericaRan2008Enrolled70ConditionsSynovitis, Osteoarthritis, Joint Diseases, Muskuloskeletal DiseasesArmsChondroitin sulphate (Condrosan), Placebo
3 · Its place in the literature

Who cites it

72 citing papers in PubMed, 9 syntheses or guidelines pooled it, 195 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Chondroitin for osteoarthritis.The Cochrane database of systematic reviews · 2015
    Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Phase II study of glucosamine with chondroitin on aromatase inhibitor-associated joint symptoms in women with breast cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2013
    Trial
  20. Trial

12 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Lukas Martin WildiOsteoarthritis Research Unit, University of Montreal Hospital Research Centre, Notre-Dame Hospital, Montreal, Canada.
Jean-Pierre Raynauld
Johanne Martel-Pelletier
André Beaulieu
Louis Bessette
Frédéric Morin
François Abram
Marc Dorais
Jean-Pierre Pelletier
Université de Montréal · CAHôpital Notre-Dame · CACegep de Sainte Foy · CAUniversité du Québec à Trois-Rivières · CAUniversité Laval · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo determine the effect of chondroitin sulphate (CS) treatment on cartilage volume loss, subchondral bone marrow lesions (BML), synovitis and disease symptoms in patients with knee osteoarthritis (OA).

methodsIn this pilot multicentre, randomised, double-blind, controlled trial in primary knee OA, 69 patients with clinical signs of synovitis were randomised to receive CS 800 mg or placebo once daily for 6 months followed by an open-label phase of 6 months in which patients in both groups received CS 800 mg once daily. Cartilage volume and BML were assessed by MRI at baseline and at 6 and 12 months; synovial membrane thickness was assessed at baseline and at 6 months.

resultsThe CS group showed significantly less cartilage volume loss than the placebo group as early as 6 months for the global knee (p=0.030), lateral compartment (p=0.015) and tibial plateaus (p=0.002), with significance persisting at 12 months. Significantly lower BML scores were found for the CS group at 12 months in the lateral compartment (p=0.035) and the lateral femoral condyle (p=0.044). Disease symptoms were similar between the two groups.

conclusionCS treatment significantly reduced the cartilage volume loss in knee OA starting at 6 months of treatment, and BML at 12 months. These findings suggest a joint structure protective effect of CS and provide new in vivo information on its mode of action in knee OA.

Indexed as

AdultAgedAnti-Inflammatory Agents, Non-SteroidalBone Marrow DiseasesCartilage, ArticularChondroitin SulfatesDrug Therapy, CombinationEpidemiologic MethodsFemaleHumansMagnetic Resonance ImagingMaleMedication AdherenceMiddle AgedOsteoarthritis, KneePatient SelectionAnti-Inflammatory Agents, Non-SteroidalChondroitin Sulfates

Identifiers

PMID21367761
PMCPMC3086081
OpenAlexW2106085759

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.